<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292067</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190991</org_study_id>
    <secondary_id>2019-A02632-55</secondary_id>
    <nct_id>NCT04292067</nct_id>
  </id_info>
  <brief_title>Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis</brief_title>
  <acronym>MICROBIART</acronym>
  <official_title>Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study aims to compare the biodiversity of intestinal microbiota
      between spondylarthritis (SPA) or rheumatoid arthritis (RA) patients and healthy volunteers,
      by microbiota DNA sequencing in order to further and respond the prior results, which
      suggested that there is a specific dysbiosis for each of the 2 diseases. A comparative
      analysis will allow to identify the biomarkers of the specific bacteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As secondary objectives, the study aims to analyse the relation between different clinical
      parameters such as age, gender, duration of the disease, or the nature of ongoing treatment,
      and the the composition of intestinal microbiota, and identify dysbiosis of bacteria, which
      will be specific functional signatures of intestinal microbiota in SPA and/or RA.

      This study will be performed in the rheumatology department in Ambroise Paré hospital of APHP
      group in France.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bacteria analysis</measure>
    <time_frame>At the end of study, up to 4 years</time_frame>
    <description>Quantitative analysis of repartition of bacteria in each group and the comparison between groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota composition</measure>
    <time_frame>At the end of study, up to 4 years</time_frame>
    <description>Intestinal microbiota composition will be analysed</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Spondyloarthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>patients with SPA</arm_group_label>
    <description>100 SPA patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjets</arm_group_label>
    <description>200 healthy subjets in control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with RA</arm_group_label>
    <description>100 RA patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Faecal sampling</intervention_name>
    <description>Faecal sampling at baseline</description>
    <arm_group_label>Healthy subjets</arm_group_label>
    <arm_group_label>patients with RA</arm_group_label>
    <arm_group_label>patients with SPA</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Faecal sampling at baseline for each subject
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Adult patient diagnosed spondyloarthritis or rheumatoid polyarthritis;

          -  Healthy adult subjects free of chronic pathology.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients:

          -  Patient ⩾ 18 years;

          -  Diagnosed as spondyloarthritis (SpA) according ASAS classification, or rheumatoid
             polyarthritis according ACR/EULAR;

          -  Affiliated to a social security scheme;

          -  Have signed the written informed consent form.

        Healthy control subjects:

          -  Adult women and men;

          -  Subjet free of chronic pathology;

          -  Affiliated to a social security scheme;

          -  Have signed the written informed consent form.

        Exclusion Criteria:

        Patients:

          -  Patients unable to understand the proposed study and/or sign a informed consent form;

          -  Pregnant women or breast feeding women;

          -  Patient ⩾ 18 years;

          -  Patients under guardianship or curatorship;

          -  Have taken antibiotic 1 month prior to inclusion or digestive coloscopy 6 months prior
             inclusion;

          -  Presenting acute or chronic severe pathology may likely to interfere with the
             interpret of outcome;

          -  Foreign patients under french AME scheme;

          -  Patients had have participated in the prior study Microbiart.

        Healthy control subjects:

          -  Subjects unable to understand the proposed study and/or sign a informed consent form;

          -  Pregnant women or breast feeding women;

          -  Subjects &lt; 18 years;

          -  Subjects under guardianship or curatorship;

          -  Presenting acute or chronic severe pathology may likely to interfere with the
             interpret of outcome;

          -  Refusal of subjects to participate to the study;

          -  Foreign patients under french AME scheme;

          -  Subjects had have participated in the prior study Microbiart.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxime BREBAN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Rhumatologie, Hôpital Ambroise Paré, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maxime BREBAN, MD, PhD</last_name>
    <phone>+ 33 1 49 09 56 72</phone>
    <email>maxime.breban@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Rhumatologie, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Maxime BREBAN, MD, PhD</last_name>
      <phone>+33 1 49 09 56 72</phone>
      <email>maxime.breban@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Breban M, Tap J, Leboime A, Said-Nahal R, Langella P, Chiocchia G, Furet JP, Sokol H. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017 Sep;76(9):1614-1622. doi: 10.1136/annrheumdis-2016-211064. Epub 2017 Jun 12.</citation>
    <PMID>28606969</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spondyloarthritis</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

